UPC APP 43889/2024

—·EP3167888: TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Verfahrensdetails: Status
—
Verfahrensart
Verfahrensantrag
Kategorie
Sonstige prozessuale
Parteien: Kläger
Alexion Pharmaceuticals, Inc.
Vertreter: Elena Hennecke (Freshfields Bruckhaus Deringer)
Beklagte
Amgen Technology (Ireland) Unlimited Company
Amgen N.V.
Amgen GmbH (Germany)
Amgen GmbH (Austria)
Amgen AB
Amgen S.A.S.
Amgen s.r.l.
Amgen Biofarmacêutica Lda.
Amgen Zdravila D.O.O.
Vertreter: Tilman Müller-Stoy (Bardehle Pagenberg)
Division: Court of Appeal
Richter: Klaus Grabinski · President of the Court of Appeal
Peter Blok · Legally qualified judge and judge-rapporteur
Emanuela Germano · Legally qualified judge
Technology: Organic Chemistry
Sprache: —
Erste Entscheidung: 30. Juli 2024

Entscheidungen

2024-07-30
BerufungsentscheidungGeneric application
The Court of Appeal rejected Alexion Pharmaceuticals' request to expedite the appeal against the Hamburg Local Division's refusal to grant provisional measures against Amgen, holding that the circumstances were not sufficiently urgent to justify shortening the time period for the respondents to lodge their statement of response.
Rechtsfragen:Expedition of appealR.9.3(b) RoPShortening of deadlinesProvisional measures appealR.225(e) RoP

Dokumente